Objective-Therapeutic hypothermia is successfully used, for example, in cardiac surgery to protect organs from ischemia.
A ntithrombotic treatment is one of the most often used medical therapies, with major benefits for patients. 1 However, the side effects associated with antithrombotic therapy can cause severe and even life-threatening complications. 2, 3 Antiplatelet drugs are particularly troublesome because of their long half-life and the lack of effective antidotes. 4 In cardiac surgery, especially when combined with extracorporeal circulation, platelet inhibition could be of major benefit. 5 However, because postoperative bleeding complications with long-acting antiplatelet drugs are feared, therapeutic platelet inhibition is preferentially avoided. We describe here a novel pharmacological strategy that uses hypothermia to tightly control and thus allow broadening of the application of platelet inhibition and potentially reducing bleeding complications.
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Therapeutic hypothermia is already widely used to reduce oxygen requirements and to protect organs from ischemia. 6 In cardiac surgery, hypothermia is typically established temporarily with the heart-lung machine during coronary artery bypass grafting (CABG), 7, 8 whereas deep hypothermic circulatory arrest is an integral component of surgery for congenital heart disease 9 and is used in adult patients for the repair of thoracic aortic dissections, 10 as well as in neurosurgical operations for the treatment of cerebral aneurysm. 11 However, therapeutic hypothermia used in clinical settings, such as cardiac surgery, has also been associated with platelet activation, aggregation, sequestration, and (micro)vascular thrombus formation. [12] [13] [14] [15] [16] [17] [18] This may result in fatal thrombotic events, 19, 20 thrombocytopenia, 20, 21 and severe bleeding complications, in particular postoperatively. 9, 13, 22, 23 Therefore, these complications indicate a need for a pharmacological approach that prevents hypothermia-associated platelet activation and after rewarming provides postoperatively reinstalled full platelet function.
Inhibiting the glycoprotein (GP) IIb/IIIa (␣IIb␤3, CD41/ CD61) represents one of the most effective strategies for platelet inhibition. 24 In the setting of cardiac surgery, preoperative treatment with the commercially available GPIIb/IIIa blockers tirofiban and eptifibatide, which block GPIIb/IIIa irrespective of its conformation, has been reported to preserve platelet function during cardiac pulmonary bypass. [25] [26] [27] However, tirofiban and eptifibatide are not optimal candidates for the desired indication because of their half-lives of 1.5 to 2 hours. 25 Furthermore, a significant side effect of conformation-unspecific GPIIb/IIIa blockers is their inhibitory effect on all circulating platelets, which also carries a risk for bleeding complications. 24,25,28 -30 We have previously described a single-chain antibody (scFv) directed against GPIIb/IIIa that selectively blocks the activated form of the receptor only, potentially providing additional advantages compared with the already successfully clinically used GPIIb/IIIa blockers. 31 In addition, this recombinant antibody can be genetically manipulated, 32 thereby providing an ideal basis for new pharmacological strategies. Therefore, we hypothesized that the fusion of this anti-GPIIb/IIIa with a temperature-sensitive molecule might provide temperaturedependent control of platelet inhibition. The molecule chosen for this approach is an elastin-mimetic polypeptide (EMP), which belongs to a family of repetitive polypeptides derived from consensus sequences, including tetrapeptide (VPGG), pentapeptide (VPGVG) or (VPAVG), and hexapeptide (APGVGV) repeat motifs of the primary structure of mammalian tropoelastin. 33 These peptides are characterized by an inverse temperature transition, where the largely unstructured elastin repeats gain ␤-sheet structure at temperatures greater than the transition temperature (T t ). 34 This specific property has prompted the promising development of several EMP-based biotechnological applications, such as protein purification and nanopartnering, 35 temperature-dependent linker peptides, 36, 37 hyperthermiamediated targeting of tumors, 38 and drug delivery. 39 In this study, we describe the successful fusion of EMP to an activation-specific GPIIb/IIIa-blocking scFv. In vitro and in vivo experiments show that the EMP-scFv enables selective hypothermia-induced antiplatelet therapy. We propose a structural model of the EMP-scFv fusion protein to illustrate how the ␤-spiral conformational transition of EMP prevents scFv from inhibiting GPIIb/IIIa at 37°C but not at hypothermia. Overall, this is the first report on the design and testing of a highly potent antiplatelet drug that can be turned on/off by medically used hypothermia.
Methods
For detailed methods, please see the supplemental materials (available online at http://atvb.ahajournals.org).
Generation of the EMP-scFv Fusion Construct
A recombinant clone encoding EMP and a short linker sequence was cloned into the pET39b(ϩ) vector and then subcloned into pHOG-21 bacterial expression vector already containing scFv cDNA. 31 
Expression of EMP-scFv Construct in Escherichia coli and Protein Purification
The EMP-scFv fusion protein was expressed in E. coli, and the insoluble fraction was purified using Ni 2ϩ -agarose beads.
Circular Dichroism and Thermal Transition Profile Monitoring
Circular dichroism (CD) spectra were recorded on a Jasco J-810 spectropolarimeter, and thermal transition curves were plotted using the mean residue ellipticity.
In Silico Structural Analysis of EMP-scFv Fusion Peptide
A model of scFv was generated using SWISS-MODEL server and Protein Data Bank entry 3bn9D. 40 The structure was analyzed using PROCHECK 41 and a Tripos force field. 42 A ␤-spiral model of EMP was constructed with the Biopolymer module in Sybyl8.1. 43
Flow Cytometry
Binding to and blocking of GPIIb/IIIa was evaluated using flow cytometry as previously described. 31 
Platelet Aggregometry and Targeting of EMP-scFv to Platelet Aggregates Under Physiological Flow Conditions at Different Temperatures
The effects of EMP-scFv on platelet aggregation were analyzed using a BioRad Benchmark plate reader according to a previously established method, 44 and the microscopic analysis of platelet aggregates was assessed using an Olympus CKX41 microscope. Images of flow chamber experiments were taken with an Olympus IX81 microscope with an XM10 camera.
In Vivo Functional Evaluation of Antithrombotic Efficacy of EMP-scFv at Different Temperatures
Thrombus development was induced in carotid arteries and jugular veins of mice by local vessel injury using ferric chloride, and the antithrombotic efficacy of EMP-scFv was analyzed following a previously established protocol. 31 
Statistical Analysis
Data are presented as meanϮSD for the indicated numbers of mice and blood donors.
Results

Construction, Expression, and Purification of EMP-scFv
Cloning an EMP cDNA upstream of the scFv in pHOG-21 bacterial expression vector resulted in a 2115-bp fusion construct (EMP-scFv) ( Figure 1A ), encoding a protein consisting of 704 amino acids, with a molecular weight of approximately 70 kDa ( Figure 1B) . Western blotting using a horseradish peroxidase-coupled anti-His(6)-tag monoclonal antibody resulted in the detection of a single band, further confirming that the protein visualized by SDS-PAGE was EMP-scFv ( Figure 1C ).
CD Spectra Profiles and Thermal Transition Profiles of Recombinant Constructs
The structural feature of the scFv is a ␤-sheet. As anticipated, no significant conformational changes were observed in CD as the temperature increased to 35°C (Figure 2A ). The EMP displayed temperature-dependent conformational rearrangement from the random coil conformation (negative ellipticity near 198 nm) to the ␤-turn signature 45 (negative ellipticity near 220 nm) ( Figure 2B ). Likewise, significant conformational changes could be detected in the CD spectra of EMP-scFv fusion molecule in that the random coil (negative ellipticity near 200 nm) was rapidly replaced with the putative ␤-turn signature (negative ellipticity near 220 nm) as the temperature approached the transition point ( Figure 2C ). The negative minimum ellipticity of the fusion protein at high temperature was slightly shifted from that of EMP, indicating an interaction between 2 components of the fusion protein.
The transition curves of the EMP demonstrated a typical unfolding/folding model representing a 2-state transition ( Figure 2D ). The mathematical fitting of the CD data allowed the determination of the T t resulting from conformational change of EMP as the temperature is increased. The mathematical fitting of the CD data to the van't Hoff equation allowed the determination of the T t resulting from conformational change of EMP and EMP-scFv as the temperature was increased. As Reiersen et al 34 reported, the transition temperature was calculated using a linear van't Hoff plot of ln K (equilibrium constant, K, where
as a function of 1/T and from the relation Tϭ⌬H/⌬S. 17 , respectively). The T t calculation indicated the consistent T t of approximately 26°C for 198 and 220 nm. In contrast, different T t values of EMP-scFv for the disappearance of the random coil and the appearance of the ␤-turn structure were clearly obtained from fitting of the CD data at 200 nm (15°C) and at 215 nm (28°C), strongly suggesting the presence of a multistate transition, including conformational change of EMP domain and hydrophobic interaction between the hydrophobic residues on the surface of antibody and the EMP within the fusion protein ( Figure 2E ). This thermal transition curve of EMP-scFv also suggests that structural change and hydrophobic collapse in the fusion were completed at temperatures higher than 35°C. Figure 3 shows the proposed structural model from one of the top docks for the EMP-scFv fusion construct after the conformational transition has occurred at 37°C. The location of the ␤-spiral EMP obstructs the RXD motif in the CDR3 region 
Proposed Structural Models of EMP-scFv Fusion Protein
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Temperature-Controlled GPIIb/IIIa Inhibitionof the heavy chain, which in turn inhibits binding of the scFv to GPIIb/IIIa ( Figure 3A ). This is further confirmed by a 90°r otation around the y-axis, which demonstrates the complementarity of the ␤-spiral of EMP for the antibody ( Figure 3B ), particularly when displayed on a larger scale ( Figure 3C ).
Temperature-Specific Binding of EMP-scFv and Inhibition of Fibrinogen Binding to Platelets
The function of the scFv component of the fusion molecule was evaluated by flow cytometry. A significantly higher level of EMP-scFv binding to human activated platelets was evident when experiments were conducted at 22°C, whereas the binding of the fusion protein to activated platelets was totally abolished when the temperature of the assay was increased to 37°C ( Figure 4A ). No binding of the EMP-scFv recombinant protein to resting platelets was detected, regardless of the temperature used in the experiment ( Figure 4A ). In a concentration-dependent manner, EMP-scFv significantly reduced the level of fibrinogen binding to human activated platelets at 22°C, reaching almost the same inhibitory levels as observed with the positive control abciximab (ReoPro), which is a clinically used humanized Fab fragment blocking GPIIb/IIIa ( Figure 4B ). Binding of fibrinogen to activated platelets by EMP-scFv was not inhibited at 37°C ( Figure 4B ). Fibrinogen did not bind to resting platelets regardless of the temperature used ( Figure 4B ). To further demonstrate the temperature-dependent blockade of the ligand-binding pocket of GPIIb/IIIa by EMP-scFv, the binding of PAC-1, which is a monoclonal antibody that binds selectively to the ligand binding pocket of activated GPIIb/ IIIa, was evaluated. EMP-scFv inhibited the binding of PAC-1 to activated platelets at 22°C but not at 37°C (Supplemental Figure I) . Rewarming experiments demonstrated that after binding to activated platelets at 22°C, EMP-scFv did not dissociate from GPIIb/IIIa on increasing the temperature to 37°C ( Figure 4C) . Furthermore, flow cytometry confirmed the ability of EMP-scFv to bind to activated human platelets (Supplemental Figure IIA) and to inhibit binding of fibrinogen (Supplemental Figure IIB) to these platelets at 32°C, a mild form of hypothermia increasingly used to treat out-of-hospital cardiac arrests. 46 To confirm that the blocking effect observed was due to the binding of the scFv component of the fusion protein to the activated platelets, we generated EMP alone following the same approach used to purify EMP-scFv and tested its binding to platelets. After generating a protein of approximately 35 kDa (Supplemental Figure IIIA) , our in vitro flow cytometry experiments demonstrated that EMP alone did not bind to either resting or activated platelets, regardless of the temperature used in the experiments (Supplemental Figure  IIIB) . Furthermore, flow cytometry demonstrated that EMPscFv did not activate platelets, as the fusion protein had no effect on binding of PAC-1 (Supplemental Figure IVA) or P-selectin expression (Supplemental Figure IVB) .
Temperature-Dependent Binding of EMP-scFv to Platelet Aggregates Under Flow Conditions and Temperature-Dependent Inhibition of Platelet Aggregation by EMP-scFv
To demonstrate that the fusion construct EMP-scFv is targeted to platelet aggregates, flow chamber experiments were performed. Hypothermic temperatures (22°C) caused binding of EMP-scFv to platelet aggregates, but normothermic temperatures (37°C) did not ( Figure 5A ). As a functional evaluation of platelets, effective inhibition of ADP-driven platelet aggregation by EMPscFv at 22°C but not at 37°C was demonstrated using a 96-well plate-based light transmission aggregometry approach ( Figure  5B ). To further assess the effect of EMP-scFv on platelet aggregation, aggregate formation was directly visualized in microscopy. EMP-scFv inhibited aggregation of activated human platelets at 22°C but not at 37°C ( Figure 5C ).
Temperature-Specific In Vivo Antithrombotic Effects of EMP-scFv
As a final proof of the newly described strategy of a temperature-dependent drug, we performed in vivo experiments in mouse thrombosis models. As a first step, flow cytometry using mouse whole blood was performed to show that EMP-scFv bound to activated murine platelets at 22°C but not at 37°C (Supplemental Figure VA) . EMP-scFv did not bind to resting mouse platelets at either 22°C or 37°C (Supplemental Figure VA) . Furthermore, flow cytometry demonstrated a significant decrease in fibrinogen binding to activated mouse platelets at 22°C in the presence of EMPscFv, whereas the fusion protein EMP-scFv had no effect on the binding of fibrinogen to mouse activated platelets in the experiments conducted at 37°C (Supplemental Figure VB) .
To demonstrate the advantages of temperature-dependent, activation-specific GPIIb/IIIa blockade by EMP-scFv on arterial thrombosis in vivo, we chose a ferric chlorideinduced mouse carotid artery thrombosis model. The EMPscFv significantly prolonged the occlusion time in mice injected with the fusion protein at 28°C compared with the control group, showing a platelet-inhibitory effect similar to that observed with eptifibatide ( Figure 6A ). In contrast to this, at 37°C EMP-scFv was not active and did not prolong the arterial occlusion time ( Figure 6A) .
Lastly, we examined the temperature-dependent antithrombotic effects of EMP-scFv in a model of jugular venous thrombosis. The percentage of initial blood flow showed significantly higher levels of blood flow 15 minutes after the injury in mice injected with EMP-scFv at 28°C, compared with the control group and those experiments conducted at 37°C ( Figure 6B ). The effects on the jugular venous blood flow of EMP-scFv at 28°C are comparable to the clinically used GPIIb/IIIa blocker eptifibatide ( Figure 6B ).
Discussion
In this study, we investigated whether the fusion of an EMP to an activation-specific GPIIb/IIIa-blocking scFv enabled selective hypothermia-induced antiplatelet therapy. To achieve this, we fused EMP to the anti-GPIIb/IIIa-scFv, expressed this fusion construct in bacteria, and purified the protein. To illustrate how the ␤-spiral conformation of EMP may prevent the scFv from inhibiting GPIIb/IIIa at 37°C, we propose a structural model of the EMP-scFv fusion. This model indicates that the ␤-spiral EMP obstructs the scFv from binding to and in turn inhibiting GPIIb/IIIa. Below the conformational-transition temperature, ie, at 22°C, EMP is reported to adopt a random unstructured conformation. 34 The random EMP conformation would not efficiently preclude the scFv from interacting with and inhibiting GPIIb/IIIa. The EMP-anti-GPIIb/IIIa-scFv fusion protein proved to be thermally responsive, as it demonstrated significant affinity for activated platelets at 22°C and 32°C but not at 37°C. The binding of fibrinogen to activated platelets was totally abolished in the presence of EMP-anti-GPIIb/IIIa-scFv at 22°C and 32°C, but it was not influenced at 37°C. We were also able to show that EMP-scFv prevented aggregation of activated platelets at 22°C but not when the temperature was increased to 37°C. In addition, our in vivo studies further demonstrated the antithrombotic efficacy of EMP-scFv, as the development of a thrombus in carotid arteries and jugular veins of mice treated with EMP-scFv was inhibited at 28°C, whereas no inhibition was observed at 37°C. This indicates that EMP-driven conformational change allows for temperature-dependent binding of scFv and hypothermiaspecific inhibition of activated GPIIb/IIIa receptors on platelets. This was further confirmed by demonstrating the inability of EMP alone to bind to platelets regardless of their activation state or temperature.
Mild (31°C to 34°C), moderate (25°C to 30°C), and deep hypothermia (Ͻ20°C) are routinely used in cardiac surgery
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Temperature-Controlled GPIIb/IIIa Inhibitionduring extracorporeal circulation and especially for deep hypothermic circulatory arrest. 7, 8 Furthermore, hypothermia has also been used to lower patients' body temperature during long-lasting neurosurgical procedures, 11 and more recently it has been successfully applied to improve the recovery of patients after out-of-hospital cardiac arrest. 46 -48 However, in vitro and in vivo experiments have shown that hypothermic temperatures can induce platelet activation and lead to a rise in microvascular thrombus formation via platelet activation, resulting in fibrinogen binding to GPIIb/IIIa receptor. 15, 16, 18 Furthermore, studies have shown that 33% to 88% of patients undergoing open-heart surgery experience some degree of postoperative neurological impairment 49 and cognitive dysfunction. 50 Hypothermia-induced platelet aggregation has also been shown to be closely related to cognitive decline after coronary artery bypass surgery. 13 Neurological dysfunction after hypothermia exposure may therefore be caused by impaired perfusion of the microvasculature caused by hypothermia-induced platelet aggregates. 13, 14 In addition, hypothermia has been reported to cause microinfarctions of the liver caused by sequestered platelets, as well as thrombus formation in the pancreatic microcirculation leading to acute pancreatitis. 20, 51 Therefore, to inhibit platelet aggregation, preserve platelet function, and to avoid hemostatic dysfunction and platelet-mediated thrombosis during hypothermia, it is highly desirable to prevent hypothermia-associated platelet activation and platelet loss. At hypothermia, our EMP-scFv fusion protein was a highly potent blocker of the activated form of the GPIIb/IIIa receptor. Our findings demonstrated that platelet fibrinogen binding and aggregation were significantly inhibited by the EMP-scFv at 22°C but not at 37°C. These temperature-dependent antiaggregation effects of EMP-scFv are further supported by our flow chamber experiments, which showed that hypothermic temperatures induced the binding of EMP-scFv to platelet aggregates under physiological flow conditions. Furthermore, we demonstrated that once bound to activated platelets at hypothermic conditions, EMP-scFv did not dissociate from the cells following the increase in temperature. By doing so, the fusion protein prevented the exposure of the unblocked active form of GPIIb/IIIa, thus inhibiting binding of fibrinogen and thrombus formation on rewarming. Therefore, the major advantage of the newly described temperature-steered GPIIb/IIIa inhibitor is its potential to protect platelets and prevent thrombosis during clinical settings in which hypothermia is used but provide fully functional platelets on rewarming of the patient. It is evident that the temperature-dependent binding of EMP-scFv to activated platelets was driven by the temperature-dependent conformational change of the EMP component of the fusion protein. We hypothesize that at lower temperatures, the EMP portion of the fusion protein is in a loose, fully expanded state, referred to as a random coil. 52 However, as the temperature is increased, the EMP segment of the fusion protein collapses to form a ␤-sheet. [52] [53] [54] This results in masking of the binding site on the anti-GPIIb/IIIa scFv, which would explain our data obtained at 37°C, where the binding of EMP-scFv to platelets, as well as its ability to inhibit fibrinogen binding and ADP-driven platelet aggregation, was completely omitted. The in silico structural analysis of the EMP-scFv fusion protein supports this hypothesis. The RXD motif in the CDR3 region of the heavy chain, which constitutes the binding site of the anti-GPIIb/IIIa antibody, 31 is masked by the ␤-spiral structure of the EMP and thus not accessible for binding to GPIIb/IIIa at 37°C. Therefore, this further confirms the ability of a temperature-responsive protein, such as EMP, to exert a novel control over an scFv function during hypothermic conditions.
Although the thermal transition profile of EMP-scFv revealed a transition temperature of 28°C, the fusion protein was still capable of binding to activated platelets and significantly inhibiting the binding of fibrinogen at 32°C. This is most likely because at 32°C, the EMP-scFv has not completely adopted the ␤-turn structure, suggesting that the RXD motif in the CDR3 region has not been completely blocked by EMP and is thus still capable of binding to activated form of GPIIb/IIIa. Previous studies have shown that the drop in protein concentration, as well as the properties of the accompanying fusion protein, can result in the increase of the real transition temperature. 35, 55 Therefore, because the concentration of EMP-scFv used in our flow cytometry experiments was no more than one fifth that applied in the CD studies, it is not unusual to see the binding of EMP-scFv to the activated platelets at 32°C, which is 5°C above its transition temperature determined by a CD assay. Drug activity at this temperature broadens the potential use of the newly described temperature-controlled strategy for the increasingly widely used mild therapeutic hypothermia to increase the survival rate and improve neurological outcome in patients after out-of-hospital cardiac arrest. 46 -48,56 -58 The limited clinical data available suggest that pharmacological platelet inhibition during CABG with aspirin or clopidogrel protects patients from ischemic events. 59, 60 Furthermore, administration of GPIIb/IIIa blockers, such as eptifibatide and tirofiban, in the preoperative period of CABG has been reported to decrease the incidence of perioperative myocardial infarction and platelet loss, as well as the need for minor transfusions during CABG. 26 Also, biochemical markers show less activation of the hemostatic and inflammatory system. 61 However, despite these initial promising reports about the effects of GPIIb/IIIa blockers during cardiac surgery, 26, 62, 63 the currently available agents, particularly abciximab, are too long-acting to provide controllable platelet inhibition that is restricted to the time period of the actual surgical intervention and thus are feared to result in bleeding complications after the surgical procedure. 59,60,64 -67 Overall, because of the dichotomy of antithrombotic (antiischemic) and antihemostatic effects of the currently clinically available antiplatelet drugs, strong evidence for the overall benefit of platelet inhibition in CABG has not been demonstrated. However, reversible antiplatelet compounds have been suggested to represent an ideal approach for platelet protection in patients undergoing CABG, providing support for the drug development strategy outlined in this study. 60 Conformation-unspecific binding of GPIIb/IIIa inhibitors may have 2 major disadvantages. It has been postulated that their conformation-unspecific, ligand-mimetic binding can cause paradoxical platelet activation. 68 Furthermore, the inhibitory effect 
Temperature-Controlled GPIIb/IIIa Inhibitionof the conformation-unspecific blockade of all GPIIb/IIIa receptors on all circulating platelets is seen as a major reason for bleeding problems. In contrast, selective activation-specific blockade of GPIIb/IIIa by the scFv described promises a substantial advantage in regard to bleeding risks, as it does not prolong bleeding time in contrast to the currently clinically used conformation-unspecific GPIIb/IIIa inhibitors. 31 Moreover, unlike clinically used GPIIb/IIIa blockers, such as abciximab and eptifibatide, which in addition to blocking platelets have also been shown to bind to ␣ v ␤ 3 and other integrins on vascular cells, 69, 70 extensive tests in our laboratory did not reveal binding of the described scFv to cells other than platelets. 31 We could also confirm platelet specificity for the EMP-scFv fusion construct (data not shown). Such a unique cell and function specificity is an ideal basis for a therapeutic approach, avoiding unwanted side effects, which could be caused otherwise by binding to and blocking of other cell types.
In the current study, in vivo evaluation of temperatureregulated EMP-scFv in carotid arteries of mice revealed an antithrombotic effect of the fusion protein, comparable to that of the clinically used GPIIb/IIIa blocker eptifibatide, at 28°C but not at 37°C. Furthermore, the observation that EMP-scFv exhibited significant antithrombotic effects in our jugular vein model under hypothermic conditions suggests that this strategy could prove beneficial in relation to a prophylactic approach during surgery in preventing venous thrombosis and pulmonary embolism. Overall, the administration of a temperature-dependent and activation-specific GPIIb/IIIa receptor blocker developed in this study is a highly attractive concept because of the potential of this approach to achieve an unprecedented optimal therapeutic control of platelet function during and after hypothermia.
In conclusion, we have designed a novel and unique pharmacological strategy describing a potential drug that integrates temperature-sensitive function with conformation selective binding. Our in silico, in vitro, and in vivo data demonstrate that a fusion protein consisting of an elastin-mimetic protein (EMP) and an anti-GPIIb/IIIa scFv is a promising agent to be used for the prevention of thrombosis during surgical procedures performed under hypothermic conditions. This novel pharmacological strategy promises to provide antithrombotic protection during surgery, to conserve platelets against hypothermiainduced activation and to ensure fully functional platelets for intact hemostasis on rewarming of the patient. This is the first description of a broadly usable pharmacological strategy, which uses temperature to fully control drug activity.
